Safety, Screening and Risk Management
Psychedelic-Assisted Medicine: Science and Practice
Learning objectives for this lesson:
- Describe the acute effects of psilocybin, MDMA and esketamine on blood pressure and heart rate, and explain how protocols time their monitoring.
- Explain how MDMA causes hyperthermia and hyponatremia, and why these harms concentrate in settings outside clinics.
- Calculate a corrected QT interval and explain how ibogaine's effects on the heart relate to the deaths reported in unregulated settings.
- Weigh the evidence linking 5-HT2B receptors to valvular heart disease with repeated dosing, and describe ketamine-associated cystitis.
- Summarize the evidence on psychosis, mania, suicidality, hallucinogen persisting perception disorder and extended difficulties, distinguishing trial findings from population and survey findings.
- Calculate a risk difference, a relative risk and a number needed to harm from published adverse event counts, and interpret their confidence intervals.
- Apply psychiatric and medical exclusion criteria, thresholds and medication review to referrals, distinguishing deferral from exclusion and identifying criteria that may exclude people unfairly.
- Describe the stepwise management of difficult experiences and medical events, discharge criteria and aftercare, including follow-up for suicidality.
- Describe the peer support and sanctuary services available outside clinics and what each can and cannot do, and state the legal protections and limits that apply in Canada, including those on regulated practitioners.
This course was developed by Dr. Kiffer G. Card.
Physical Risks: Blood Pressure, MDMA Toxicity, Ibogaine, Heart Valves and the Bladder
Content note
This section discusses deaths associated with ibogaine and with MDMA used outside clinics. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).
Introduction
Lesson 3 described how psychedelics act on receptors and how the body absorbs, converts and clears them. This lesson asks what can go wrong, for whom, and how clinicians reduce the chance that it does, taking physical risks, psychiatric risks, screening and the management of events in turn.
Learning Objectives
- 1.1 Describe the acute effects of psilocybin, MDMA and esketamine on blood pressure and heart rate, and explain how clinical protocols monitor them.
- 2.1 Explain how MDMA can cause hyperthermia and hyponatremia, and why these risks concentrate in settings outside clinics.
- 3.1 Explain how ibogaine prolongs the QT interval, calculate a corrected QT interval with the Bazett and Fridericia formulas, and summarize the evidence on deaths associated with ibogaine.
- 4.1 Describe the 5-HT2B receptor hypothesis of drug-induced valvular heart disease and weigh the evidence that links it to repeated psychedelic or MDMA use.
- 4.2 Describe ketamine-associated cystitis and explain how its risk depends on dose and frequency of use.
A risk is the probability that a harm occurs, and its severity is how bad the harm is: a brief rise in blood pressure during a psilocybin session is common and mild, while a fatal heart rhythm after ibogaine is rare and catastrophic. Trial participants are screened, dosed and monitored, while most people who use psychedelics do so outside any clinic, so evidence from one setting does not transfer automatically to the other. The safety evidence is also uneven. A meta-analysis of 114 studies of classic psychedelics with 3,504 participants found no serious adverse events among healthy participants and serious adverse events in about 4 percent of participants with pre-existing neuropsychiatric conditions, and only 16 of the 68 analyzed studies published since 2005 (23.5 percent) described systematic assessment of adverse events (Hinkle et al., 2024). An earlier review of 44 clinical studies with 598 patients, which also included MDMA, likewise judged adverse events to be poorly defined and probably under-reported (Breeksema et al., 2022). Table 6.1 previews the physical risks in this section.
Table 6.1. The main physical risks examined in Section 1, with the mechanism behind each and the setting in which reported harms concentrate.
| Agent | Physical risk | Mechanism in brief | Where harms concentrate |
|---|---|---|---|
| Psilocybin, MDMA, esketamine | Transient rises in blood pressure and heart rate | Sympathetic (fight or flight) activation | People with heart or vascular disease |
| MDMA | Hyperthermia and hyponatremia | More heat made and less lost; vasopressin release with heavy fluid intake | Hot, crowded events outside clinics |
| Ibogaine | QT prolongation, arrhythmia and death | Block of the hERG potassium channel | Unregulated settings; people with heart disease or other drug use |
| MDMA and possibly classic psychedelics | Valvular heart disease | Activation of 5-HT2B receptors on valve cells | Chronic heavy or repeated use |
| Ketamine | Ulcerative cystitis | Inflammation of the bladder lining | Frequent, high-dose non-medical use |
1.1 Blood Pressure and Heart Rate
Most of the drugs in this course raise blood pressure and heart rate for a few hours, as part of the activation of the sympathetic nervous system that Lesson 3 explains. In healthy participants the rise is usually modest and brief; in people with uncontrolled hypertension or heart disease it carries more risk, which is why trials have excluded them (Johnson, Richards & Griffiths, 2008; Vizeli & Liechti, 2017). The box below defines the terms used to describe these changes.
Reading blood pressure and heart rate
Systolic blood pressure is the pressure in the arteries when the heart contracts, and diastolic blood pressure is the pressure between beats. Both are measured in millimetres of mercury (mmHg) and written as, for example, 120/80 mmHg.
Tachycardia is a heart rate above 100 beats per minute, and an excursion is a temporary rise above a set threshold during a session.
1.1.1 Psilocybin
A 2026 analysis pooled 536 psilocybin sessions (oral doses of 20 to 47 mg) among 368 participants in 14 studies at Johns Hopkins University since 1999; it was posted as a preprint in April 2026 and, as of October 2026, had not been peer reviewed (Nayak et al., 2026). The median peak systolic pressure was 145 mmHg, a median rise of 22 mmHg, reached about 90 minutes after the dose and close to baseline again by 300 minutes. Systolic pressure exceeded 170 mmHg in 6.0 percent of sessions and 180 mmHg in 3.2 percent, for medians of 8.5 and 10 minutes respectively, and staff gave antihypertensive medicine in one session. A 2026 narrative review reported pooled mean increases in supervised studies of about 19.0 mmHg systolic and 8.7 mmHg diastolic, largest about 60 to 90 minutes after dosing, and cautioned that the picture may change for people with heart disease, people taking interacting medicines and mushroom products whose alkaloid content varies more than tenfold (Szarpak et al., 2026).
1.1.2 MDMA and Esketamine
MDMA's effects are larger. In nine pooled laboratory studies in which 166 healthy participants received 75 or 125 mg, systolic pressure rose above 160 mmHg in 33 percent, heart rate above 100 beats per minute in 29 percent and body temperature above 38°C in 19 percent, more often after the higher dose; no serious adverse events occurred, and the authors judged the risks likely to be higher in people with cardiovascular disease (Vizeli & Liechti, 2017). For esketamine, the nasal spray sold as Spravato (Lesson 8), the prescribing information states that blood pressure rises at all recommended doses, peaks about 40 minutes after a dose and lasts about four hours, and that 3 to 19 percent of treated patients had rises of at least 40 mmHg systolic or 25 mmHg diastolic in the first four weeks, compared with 1 to 4 percent on placebo (Janssen, 2026). Clinicians measure blood pressure before each dose, weigh the risk above about 140/90 mmHg, measure again at about 40 minutes and monitor for at least two hours. Figure 6.1 compares the two time courses with their monitoring windows.
Monitoring is timed to the drug: a protocol that measured blood pressure only at the start and end of a psilocybin session would miss the peak at 90 minutes. Section 3 returns to the thresholds that decide eligibility. The next risks arise mainly outside clinics.
2.1 MDMA, Body Temperature and Water Balance Outside Clinics
Two serious harms of MDMA arise from its effects on the body's control of heat and water; neither is common, and both can be fatal. Hyperthermia is a rise in core body temperature above its normal range. In placebo-controlled laboratory studies, moderate doses of MDMA raised body temperature by about 0.4°C and higher doses by about 0.7°C, while some studies of people using MDMA in dance clubs found average increases above 1.0°C, which Parrott (2012) attributed to activity, heat and overcrowding. MDMA increases heat production and delays sweating, and in rare cases moderate hyperthermia progresses to severe hyperpyrexia (very high fever) for reasons that are not well understood (Parrott, 2012). Hall and Henry (2006) describe hyperpyrexia with multi-organ failure as a relatively well known form of acute MDMA toxicity.
Hyponatremia is an abnormally low concentration of sodium in the blood. Campbell and Rosner (2008) describe a "perfect storm": MDMA causes release of arginine vasopressin, the hormone that tells the kidneys to retain water, and increases thirst, while fluids are easy to obtain at events and people are told to drink a great deal. The blood becomes diluted, and the authors report serious hyponatremia and hyponatremia-associated deaths. Figure 6.2 sets out the two pathways.
The figure shows why the same drug carries different risks in different places. In the laboratory studies, participants rested, received a known dose and had their temperature measured, and even so 19 percent exceeded 38°C (Vizeli & Liechti, 2017). At a festival, a person may take a product of unknown content and strength, more than once, while dancing in heat and crowds. The harm thus arises from the combination of drug, person and setting. Clinical protocols act on all three, by fixing the dose, screening out people with heart disease and controlling the environment, while outside clinics harm reduction services work on the parts they can change. HSCI 402 develops drug checking, and Section 4 describes the peer support and sanctuary services at Canadian events.
3.1 Ibogaine, the QT Interval and Deaths
Ibogaine is an alkaloid from the root bark of the iboga shrub, used ceremonially in the Bwiti religion of West Central Africa (Lesson 2) and, around the world, in medical and non-medical settings for opioid detoxification and other substance use (Alper, Stajić & Gill, 2012). Lesson 10 examines its evidence in opioid use disorder. Its main physical danger is a disturbance of the heart's electrical recovery that appears on the electrocardiogram (ECG) as a long QT interval.
3.1.1 The QT Interval
On an ECG, the QRS complex marks the electrical activation of the ventricles, the heart's main pumping chambers, and the T wave marks their recovery, called repolarization. The QT interval runs from the start of the QRS complex to the end of the T wave (Figure 6.3).
The QT interval shortens as the heart beats faster, so it is corrected to a standard heart rate before it is compared with a threshold. The corrected value, QTc, divides the measured QT by a function of the RR interval, the time in seconds from one beat to the next. Equation 6.1 gives the two corrections in most common use.
At 60 beats per minute both corrections leave the QT unchanged; at faster rates they diverge. A scientific statement from the American Heart Association and the American College of Cardiology Foundation notes that Bazett's formula tends to give overlong values above about 85 beats per minute, treats a QTc above about 470 ms in males and 480 ms in females as prolonged, describes a QTc above 500 ms as highly abnormal (associated with a two- to threefold higher risk of a dangerous arrhythmia in congenital long QT syndrome), and advises prompt action when a drug lengthens the QTc by 60 ms or more (Drew et al., 2010).
Worked Example 6.1. A hypothetical screening ECG shows a QT interval of 440 ms at 72 beats per minute. RR = 60 ÷ 72 = 0.833 s. Bazett's QTc = 440 ÷ √0.833 = 440 ÷ 0.913 = 482 ms. Fridericia's QTc = 440 ÷ ∛0.833 = 440 ÷ 0.941 = 468 ms. The 14 ms difference can place the same tracing on either side of a 470 ms threshold. Use Calculator 6.1 to check these figures and to see the gap widen as heart rate rises.
3.1.2 How Ibogaine Affects the Heart
Studies in cells show that ibogaine and its main metabolite, noribogaine, inhibit the hERG potassium channel, which carries the current that repolarizes heart muscle cells (Koenig & Hilber, 2015; Knuijver et al., 2022). Slower repolarization lengthens the QT interval and raises the risk of torsades de pointes, a fast, irregular ventricular rhythm that can be life-threatening. Koenig and Hilber (2015) report a plasma half-life of 4 to 7 hours for ibogaine and 28 to 49 hours for noribogaine, so the cardiac risk can outlast the acute experience by days. Ibogaine can also slow the heart and lower blood pressure, which adds to the risk (Knuijver et al., 2022). Case 6.1 shows these effects under close monitoring.
Knuijver and colleagues (2022) gave a single dose of ibogaine hydrochloride (10 mg per kg) to 14 people with opioid use disorder on opioid maintenance treatment. They excluded people with heart disease, a QTc above 450 ms (men) or 470 ms (women) or QT-prolonging medicines, and recorded 12-lead ECGs at regular intervals for at least 24 hours, with magnesium planned for any QTc above 500 ms. Before dosing, participants were switched from their maintenance opioid to oral morphine for eight days, partly to remove any QT-prolonging effect of methadone.
The maximum QTc prolongation (Fridericia) was about 95 to 100 ms in a typical participant: the abstract gives an average of 95 ms (range 29 to 146), and the results table a median of 102 ms (range 40 to 168). Half of the participants exceeded 500 ms, and in 6 of 14 the QTc stayed above 450 ms beyond 24 hours. No torsades de pointes was observed, although the authors note that their ECG monitoring was not continuous and could have missed brief episodes, and all participants had severe, temporary ataxia (loss of coordination). The authors concluded that ibogaine belongs only in controlled settings with strict cardiac monitoring, and noted that the heart and liver disease they excluded is common among people with long-term illicit opioid use.
3.1.3 Deaths Associated with Ibogaine
Alper, Stajić and Gill (2012) reviewed every known death outside West Central Africa temporally related to ibogaine between 1990 and 2008. Nineteen people, 15 men and 4 women aged 24 to 54, died between 1.5 and 76 hours after taking it. In 12 of the 14 cases with adequate post-mortem data, advanced pre-existing medical conditions, mainly cardiovascular, or other drugs explained or contributed to the death. Other risk factors were seizures linked to alcohol or benzodiazepine withdrawal and the uninformed use of ethnopharmacological forms of ibogaine. A 2026 review describes the cardiac risk as rare but clinically significant and notes case reports of dangerous arrhythmias at therapeutic doses and in people without pre-existing heart conditions (Brunt, 2026). Health Canada issued a public warning in 2015 and added ibogaine to the Prescription Drug List in May 2017, citing serious and fatal adverse reaction reports (Health Canada, 2017). Lesson 10 describes trials that give ibogaine with magnesium.
4.1 5-HT2B Receptors and the Valvulopathy Question
The fourth risk would develop over months or years of repeated exposure, and it rests on a chain of reasoning from cells to people. It began with fenfluramine, an appetite suppressant later withdrawn from that use, which was linked to drug-induced valvular heart disease, in which damaged heart valves leak or narrow (Setola et al., 2003). Rothman and colleagues (2000) found that the drugs known to cause it all activated the 5-HT2B receptor, concluded that such activation is probably necessary for the disease, and recommended screening every serotonergic medicine for it. Setola and colleagues (2003) then showed that MDMA and its metabolite MDA activate human 5-HT2B receptors and make human valve cells proliferate in culture, and predicted that long-term MDMA use could cause fenfluramine-like valve disease.
Evidence in people is limited. Droogmans and colleagues (2007) examined 29 people with a history of MDMA use and 29 matched controls with blinded echocardiography (heart ultrasound); 8 of the 29 people with a history of MDMA use (28 percent) and none of the controls had abnormal valves, mostly mild to moderate regurgitation (backflow). Tagen and colleagues (2023) found that LSD, psilocybin, mescaline, DMT and MDMA or their metabolites all bind the 5-HT2B receptor at least as potently as the 5-HT2A receptor, and that all except mescaline, which could not be assessed, are partial agonists. Safety margins at typical microdoses were wider than for known valve-damaging drugs, and the authors judged valve disease a potential risk of chronic microdosing that needs study. A 2026 review judged a valve concern biologically plausible for psilocybin under chronic exposure, while noting that clinical valve injury has not been established (Szarpak et al., 2026). Table 6.2 sets out what each kind of evidence can show.
Table 6.2. The evidence on 5-HT2B receptors and valvular heart disease, by kind of study.
| Study | Kind of evidence | What it can and cannot show |
|---|---|---|
| Rothman et al. (2000) | Receptor screening in cells | A plausible mechanism |
| Setola et al. (2003) | Human valve cells in culture | The mechanism can operate; dose, time and the whole body are absent |
| Droogmans et al. (2007) | Cross-sectional study, 29 people with a history of MDMA use and 29 controls | Possible harm with repeated use; small and measured once |
| Tagen et al. (2023) | Review of cell, animal and clinical data | The evidence gap for repeated dosing |
Trials of psychedelic-assisted therapy give one to three doses, so the question presses most for microdosing, frequent maintenance sessions and heavy long-term MDMA use. A prospective study measuring heart valves before and during repeated dosing would test the hypothesis directly, and Tagen and colleagues (2023) found no animal or clinical study designed to evaluate this risk for the classic psychedelics. For these drugs the valve risk therefore remains largely speculative, resting on cell studies and on evidence from repeated MDMA use, and research on it is evolving. The flip cards apply Lesson 4's rule that findings in cells need confirmation in people.
4.2 Ketamine and the Bladder
An early description of the last physical risk came from Toronto, in 2007. Shahani and colleagues (2007), at St. Michael's Hospital and the University of Toronto, described nine people who used ketamine daily and had severe pain on urination, frequency, urgency and visible blood in the urine. Urine cultures were sterile, imaging showed thickened bladder walls and small capacity, and cystoscopy showed severe ketamine-associated ulcerative cystitis, an inflammation that strips the bladder lining. Stopping ketamine, with the bladder medicine pentosan polysulfate, appeared to give some relief.
In an online survey promoted by a dance music magazine, 1,285 of 3,806 respondents reported ketamine use in the past year, and 26.6 percent of them reported urinary symptoms, which increased with both dose and frequency of use; of 251 who described the course of their symptoms, 51 percent reported improvement after stopping (Winstock et al., 2012). Because the sample was self-selected, these percentages describe respondents only. Medical use involves lower and less frequent doses. The esketamine prescribing information reports cystitis with long-term off-label ketamine use, no esketamine-related interstitial cystitis in its studies, and more lower urinary tract symptoms than with placebo (Janssen, 2026), and reports to the United States adverse event reporting system show higher odds of urinary disorders for ketamine than for other drug classes and lower or comparable odds for esketamine (Chiappini et al., 2025). A 2025 systematic review of 27 studies of ketamine treatment for psychiatric disorders found urological symptoms in 0 to 24.5 percent of patients, mostly mild or moderate, and concluded that, on the limited data available, treatment does not appear to raise the risk, although few studies assessed long-term treatment or monitored symptoms systematically (Kerr-Gaffney et al., 2025). Lesson 8 describes ketamine-assisted psychotherapy and private ketamine clinics, where repeated dosing schedules raise this question. Try it 6.1 asks you to match each risk in this section to its safeguards.
For each risk in Table 6.1, name one safeguard that a clinical protocol uses and say whether it is available at a music festival.
Suggested answer: Screening for hypertension and timed blood pressure measurement have no festival equivalent. A clinic fixes the MDMA dose, keeps the person at rest and measures temperature (Vizeli & Liechti, 2017), while heat, crowds and unknown doses add risk at a festival. A hospital screens the ECG and monitors the heart for a day or more after ibogaine (Knuijver et al., 2022). For valve disease, the safeguard is to limit repeated exposure until evidence exists (Tagen et al., 2023), and for cystitis, medical regimens use lower and less frequent doses and monitor urinary symptoms (Janssen, 2026); both depend at a festival on the person's own pattern of use.
Most physical risks of psychedelics follow predictably from their pharmacology: they rise with dose and frequency, they are larger in people with heart disease, and the setting shapes them. Screening and monitoring reduce them, and most of the deaths reviewed here involved pre-existing illness, other drugs or settings without those safeguards, although arrhythmias after ibogaine have also been reported in people without known heart disease (Brunt, 2026). Psychiatric risks are harder to predict, because they depend on the person's history and on the experience itself, and Section 2 examines them.
Key Takeaways
- 1.1 Psilocybin, MDMA and esketamine raise blood pressure and heart rate for a few hours through sympathetic activation, and trials exclude people with uncontrolled hypertension or heart disease. In pooled Johns Hopkins sessions reported in a 2026 preprint, psilocybin raised systolic pressure by a median of 22 mmHg, with a peak at about 90 minutes and a return near baseline by 300 minutes, while esketamine's rise peaks at about 40 minutes and lasts about four hours. Monitoring must therefore be timed to the drug.
- 2.1 MDMA can cause hyperthermia by increasing heat production and delaying sweating, and hyponatremia by releasing vasopressin and increasing thirst while fluids are freely available. Heat, crowding, exertion, heavy fluid intake and products of unknown content explain why these harms concentrate at events outside clinics, where the fixed dose, screening and controlled setting of a clinical protocol are absent.
- 3.1 Ibogaine and noribogaine inhibit the hERG potassium channel, lengthening the QT interval and raising the risk of torsades de pointes, and noribogaine's half-life of 28 to 49 hours lets the risk outlast the experience by days. The QTc corrects the QT interval for heart rate: Bazett's formula divides by the square root of the RR interval and Fridericia's by the cube root, and the two can place one tracing on either side of a threshold. Most of the 19 deaths reviewed from 1990 to 2008 involved pre-existing heart disease or other drugs.
- 4.1 Drugs that activate 5-HT2B receptors have caused valvular heart disease, MDMA and MDA make human valve cells proliferate in culture, and one small study found abnormal valves in 8 of 29 people with a history of MDMA use. Trials give one to three doses and a 2023 review found no study designed to test the risk with repeated classic psychedelic dosing, so the question matters most for microdosing, frequent maintenance sessions and heavy MDMA use.
- 4.2 Ketamine-associated ulcerative cystitis, described in people in Toronto who used ketamine daily, is an inflammation that strips the bladder lining. Urinary symptoms rose with both dose and frequency of use and often improved after stopping, while medical regimens use lower and less frequent doses and esketamine studies found no esketamine-related interstitial cystitis.
Reflection
A hypothetical retreat outside Canada advertises ibogaine sessions "monitored by experienced facilitators" using a pulse oximeter and an automatic blood pressure cuff, with guests free to leave the next morning. Section 1 reported that ibogaine and its metabolite noribogaine inhibit the hERG potassium channel in cell studies; that noribogaine has a half-life of 28 to 49 hours; that in a 2022 Dutch hospital study of 14 people with opioid use disorder, half exceeded a QTc of 500 ms and 6 stayed above 450 ms more than 24 hours after the dose; and that in a 2012 review of 19 deaths between 1990 and 2008, most of those with adequate post-mortem data involved cardiovascular disease or other drugs. Using this evidence, explain why the advertised monitoring is inadequate and describe what a safer protocol would require.
Minimum 20 characters required.
Question 1: In the pooled analysis of 536 psilocybin sessions at Johns Hopkins (Nayak et al., 2026, preprint), when did systolic blood pressure typically peak?
Question 2: Which combination of effects did Campbell and Rosner (2008) describe as a "perfect storm" behind MDMA-associated hyponatremia?
Question 3: A hypothetical ECG shows a QT interval of 400 ms at a heart rate of 75 beats per minute. What is the QTc by Bazett's formula?
Question 4: Which piece of evidence on 5-HT2B receptors and valvular heart disease comes from a study of people?
Psychiatric Risks: Psychosis, Mania, Suicidality, HPPD and Extended Difficulties
Content note
This section discusses suicidal ideation, suicidal behaviour and self-injury reported in clinical trials and surveys, and lasting psychological distress after psychedelic use. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).
Introduction
Psychedelic-assisted therapy acts on the mind, so its most important risks are psychological. Lesson 5 described challenging experiences during sessions and how people make meaning of them. This section concerns psychiatric harms that are serious or that outlast the session: psychosis and mania, suicidal thoughts and behaviour, persisting perceptual disturbances and extended difficulties.
Learning Objectives
- 5.1 Summarize the evidence on psychosis and mania after psychedelic use, including the evidence on personal and family history, and explain what each study design can and cannot show.
- 5.2 Describe the suicidality findings of the COMP360 psilocybin trials and of other psychedelic trials.
- 5.3 Define hallucinogen persisting perception disorder and state what is known about how often and for how long it occurs.
- 5.4 Define extended difficulties and state what is known about how often and for how long they occur.
- 5.5 Write a precise summary of psychiatric risk that distinguishes what trials have observed from what they are too small or too selective to detect.
- 6.1 Calculate a risk difference, a relative risk and a number needed to harm from published counts, and interpret their confidence intervals.
Concern about these harms is old. Johnson, Richards and Griffiths (2008) summarize a 1960 survey by the psychiatrist Sidney Cohen of researchers who had given LSD or mescaline to research participants and patients. Among about 1,200 research participants who were not patients, one psychotic reaction lasted more than 48 hours (0.8 per 1,000) and no suicide attempts occurred; among patients, prolonged psychotic reactions occurred at 1.8 per 1,000, suicide attempts at 1.2 per 1,000 and suicides at 0.4 per 1,000. Only 44 of the 62 researchers returned the survey, so these rates are uncertain. In a 2024 meta-analysis of modern studies, about 4 percent of trial participants with neuropsychiatric conditions had a serious adverse event, including worsening depression, suicidal behaviour, psychosis and convulsive episodes, and no deaths by suicide, persistent psychotic disorders or cases of hallucinogen persisting perception disorder were reported in contemporary research settings (Hinkle et al., 2024). The evidence arrives through two windows, compared in Figure 6.4.
Neither window shows the whole picture, so each body of evidence below is read through both.
5.1 Psychosis and Mania
Psychosis is a state in which a person loses contact with shared reality, through hallucinations, delusions or disorganized thinking. Mania is a period of abnormally elevated or irritable mood with increased energy, reduced need for sleep and impaired judgement, and it defines bipolar I disorder. The concern is that in a vulnerable person, a psychedelic could trigger an episode that persists after the drug has gone. Johnson, Richards and Griffiths (2008) therefore recommend excluding anyone with a current or past psychotic disorder or bipolar I or II disorder, and anyone with a first- or second-degree relative with these disorders. Reviews suggest that psychosis is uncommon in research settings: a 2025 meta-analysis estimated its incidence at 0.2 percent in uncontrolled trials and 0.6 percent in randomized trials, from mostly low-quality studies (Sabé et al., 2025), and a 2026 systematic review found that manic symptoms after psychedelics were typically brief and self-limited, with higher risks reported in people with bipolar I disorder, a family vulnerability, polysubstance use or unsupervised use (Eskinazi et al., 2026). Because this evidence comes mainly from observational studies and small trials, research on these risks is evolving.
5.1.1 Evidence from Ontario Health Records
Two Canadian cohort studies used the health records of everyone insured in Ontario. Among 9,244,292 people aged 14 to 65 with no history of psychosis, 5,217 had an emergency department visit coded as involving hallucinogen use; within three years, 3.99 percent of them were diagnosed with a schizophrenia spectrum disorder, compared with 0.15 percent of the general population. Adjusted only for age and sex, the hazard ratio was 21.32 (95 percent confidence interval 18.58 to 24.47); after further adjustment for other substance use and mental health conditions, it was 3.53 (3.05 to 4.09), and the risk was also higher than after emergency visits involving alcohol (hazard ratio 4.66) or cannabis (1.47) (Myran et al., 2025a). A second study found that within three years of acute care involving hallucinogens, 1.43 percent of people had an episode of mania requiring acute care, compared with 0.06 percent of a matched group, a weighted hazard ratio of 5.97 (3.29 to 10.82) (Myran et al., 2025b). An emergency visit marks a severe reaction, so these people are a small minority of those who use hallucinogens, and the authors state that the results may not generalize to people who never need acute care. Some visits may also reflect the first signs of an illness already developing.
5.1.2 Evidence from Twin and Survey Studies
In 16,255 Swedish adolescent twins, psychedelic use was associated with fewer psychotic symptoms after adjustment for other drug use, but its association with manic symptoms depended on genetic vulnerability to schizophrenia or bipolar I disorder (Simonsson et al., 2024). In a longitudinal survey of adults in the United States with 12,345 followed up, psychedelic use was associated with increases in psychotic and manic symptoms only when it occurred in an illegal context, and the increase in manic symptoms was moderated by a personal history of schizophrenia or bipolar I disorder (Simonsson et al., 2025). A cross-sectional survey of 548 people found no association between lifetime use and psychotic symptoms after adjustment, including among those with a personal or family history of psychotic or bipolar disorders (Dourron et al., 2025).
5.1.3 Bipolar Disorder
In a web survey of 541 people with self-reported bipolar disorder who had used psilocybin, 32.2 percent described new or increased symptoms afterwards, most prominently manic symptoms, poor sleep and anxiety, and 3.3 percent had used emergency services (Morton et al., 2023). An open-label trial of a single 25 mg dose in bipolar II depression enrolled 19 of 70 people approached, and among the 15 reported, mania scores did not change significantly (Aaronson et al., 2024). Downey and colleagues (2024) argue that a family history of bipolar disorder should prompt stratified assessment, weighing how closely related the relative is, the type of bipolar disorder, the relative's age at onset and the participant's age, and they oppose blanket exclusion. Table 6.3 brings these studies together.
Table 6.3. Key studies of psychosis and mania after psychedelic use, with the main limitation of each.
| Study | Design | Main finding | Main limitation |
|---|---|---|---|
| Myran et al. (2025a, 2025b) | Ontario cohorts, over 9 million people | More psychotic and manic disorders after hallucinogen acute care | Severe reactions only; possible reverse causation |
| Simonsson et al. (2024) | Swedish adolescent twins | Manic symptoms depended on genetic vulnerability | Self-report at one age |
| Simonsson et al. (2025) | Longitudinal online survey | Increases only with use in illegal contexts | Purposive sample; 56 percent retention |
| Morton et al. (2023) | Survey of people with bipolar disorder | One third reported new or increased symptoms | Self-selected; self-reported diagnosis |
| Aaronson et al. (2024) | Open-label trial, bipolar II depression | No significant change in mania scores | Fifteen participants; no control group |
Taken together, the studies and reviews in this section support caution for people with a personal history of psychotic or bipolar I disorder. Downey and colleagues (2024) note that evidence on family history comes mainly from case studies and surveys, which leaves open how much a family history adds once a person has been screened and supported, a question Section 3 returns to.
5.2 Suicidality Signals in Trials
Depression carries a risk of suicide whatever the treatment, so trials must separate what a treatment causes from what the illness brings. The box below defines the terms that trial reports use.
How trials describe suicidality
Suicidal ideation means thoughts of ending one's life, from a passive wish to be dead to an active plan; suicidal behaviour includes preparatory acts and attempts; intentional self-injury is deliberate self-harm with or without suicidal intent.
A treatment-emergent adverse event begins or worsens after treatment starts, whether or not the treatment caused it, and a serious adverse event is life-threatening, fatal or requires hospitalization. Trials measure suicidality with the Columbia Suicide Severity Rating Scale (C-SSRS), and an independent data and safety monitoring board reviews unblinded safety data while a trial runs.
5.2.1 The COMP360 Phase 2b Trial
Goodwin and colleagues (2022) randomly assigned 233 adults with treatment-resistant depression to a single dose of COMP360 psilocybin at 25 mg, 10 mg or 1 mg (the control), with psychological support, after antidepressants had been stopped at least two weeks before baseline; people at clinically significant risk of suicide were excluded. Adverse events occurred in 77 percent of participants, and suicidal ideation or behaviour or self-injury occurred in all dose groups (Table 6.4).
Table 6.4. Suicidality in the COMP360 phase 2b trial by dose group (Goodwin et al., 2022; company-reported rows from Compass Pathways, 2021).
| Measure | 25 mg | 10 mg | 1 mg |
|---|---|---|---|
| Participants randomized | 79 | 75 | 79 |
| Suicidal ideation at baseline | 21 (27%) | 27 (36%) | 19 (24%) |
| Worsening of suicidal state, baseline to week 3 | 11 (14%) | 13 (17%) | 7 (9%) |
| Any suicidality adverse event (company-reported) | 7 | 6 | 4 |
| Serious suicidality adverse event (company-reported) | 4 | 4 | 1 |
| Serious events after week 3 | Suicidal behaviour (3) | Self-injury, depression, suicidal ideation (1 each) | Self-injury (1) |
The sponsor's analysis, released in December 2021, reported that all participants with these events had described suicidal thoughts before the trial, that most serious events occurred at least a week after the session, and that all suicidal behaviours occurred at least a month after it, in people who had not responded (Compass Pathways, 2021). The trial authors concluded that suicidality "demands clinical vigilance in future trials of psilocybin for depression" (Goodwin et al., 2022), and Mann (2023) called for future research to evaluate psilocybin's safety in terms of suicide risk.
5.2.2 Later and Other Trials
Two phase 3 trials of COMP360 have reported topline results only through company announcements (as of October 2026). For COMP005, which compared a single 25 mg dose with placebo in 258 participants, the company quoted its monitoring board as finding "no evidence of a clinically meaningful imbalance between treatment arms in suicidality" in either phase 3 study (Compass Pathways, 2025). For COMP006, with 581 participants, the company reported serious suicidal ideation in under 1 percent across both trials and one serious suicidal behaviour event, in the 1 mg group (Compass Pathways, 2026). Few counts by group were given, so these statements remain company-reported until the data are published. Elsewhere, a meta-analysis of individual data from seven trials found large decreases in suicidality from baseline, with acute and post-acute increases in 6.5 and 3.0 percent of participants (Zeifman et al., 2022). An open-label study of COMP360 given with an SSRI found no increase in suicidal ideation or behaviour among 19 participants (Goodwin et al., 2023). In a 2021 phase 3 trial of MDMA-assisted therapy, suicidality events of special interest occurred in 3 of 46 participants given MDMA and 5 of 44 given placebo, which the authors judged were not induced by MDMA (Mitchell et al., 2021), although Lesson 9 describes the FDA advisory committee's 2024 concern that adverse events in that program were under-recorded.
Counts of events cannot show what such an event is like for the person who has it. Case 6.2 shows a suicidality adverse event from the inside.
Wahba and colleagues (2024) described a participant in a phase 2b trial of psilocybin for treatment-resistant depression whose suicidal ideation increased after dosing and who had a prolonged period of severely restricted eating that led to destabilization and a need for support, while her depression scores improved little. In a written account, she described the experience as helpful overall and said it led to changes in her life that she valued. The authors concluded that psilocybin can lead to temporary worsening of suicidal ideation and to adverse events that outlast its acute effects, and called for qualitative study of serious adverse events alongside trials.
5.3 Hallucinogen Persisting Perception Disorder
Hallucinogen persisting perception disorder (HPPD) is the re-experiencing, after use has stopped, of perceptual distortions first experienced while intoxicated, to a degree that causes distress or impairment (Halpern, Lerner & Passie, 2018). Halpern and Pope (2003) analyzed 20 studies published between 1955 and 2001 and concluded that HPPD appears to be a genuine but uncommon disorder, sometimes persisting for months or years, reported most often after illicit LSD use and less often after LSD given in research or treatment. A later review distinguishes Type 1, brief "flashbacks", from Type 2, a chronic form that waxes and wanes, and links it consistently with dissociative symptoms and anxiety (Halpern et al., 2018). Johnson and colleagues (2008) described its incidence as unknown and advised researchers to ask about perceptual disturbances at follow-up, Halpern and Pope (2003) called for further studies of its prevalence, and a 2024 meta-analysis found no cases reported in contemporary research settings (Hinkle et al., 2024).
5.4 Extended Difficulties
Some people describe difficulties lasting weeks, months or years after a psychedelic experience without meeting the criteria for a specific disorder; researchers call these extended difficulties. Evans and colleagues (2023) collected accounts from 608 people who reported them. The most common forms were anxiety and fear, existential struggle, social disconnection, depersonalization (feeling detached from oneself) and derealization (feeling that the world is unreal). For about one third the difficulties lasted more than a year, and for about one sixth more than three years. Knowing the dose and drug and having a less difficult acute experience predicted shorter difficulties, and a guided setting predicted a narrower range. In a survey of 1,993 people about their single most difficult experience with psilocybin mushrooms, which respondents called their worst "bad trip", 11 percent said they had put themselves or others at risk of harm and, of those whose experience was more than a year earlier, 7.6 percent had sought treatment for enduring symptoms; three cases appeared associated with enduring psychotic symptoms and three with attempted suicide, while 84 percent reported benefiting (Carbonaro et al., 2016). The accordion summarizes what such surveys can establish.
Extended difficulties exist, can last for years and take recognizable forms, and knowledge of the drug, a less difficult acute experience and a guided setting are associated with milder courses (Evans et al., 2023). Risky behaviour was associated with higher estimated dose and the absence of physical comfort and social support (Carbonaro et al., 2016).
Self-selected samples cannot give incidence, since people with very distressing experiences may be more likely to respond, and associations with setting may reflect differences between the people who choose guided and unguided use. Trials follow every participant, as Case 6.2 shows, but their samples are small and their follow-up rarely exceeds a few months.
5.5 Stating Psychiatric Risk Precisely
Statements about psychedelic safety often compress this evidence, and some claim more than it supports. A claim that no serious adverse events occur in screened participants conflicts with the roughly 4 percent of patient participants who had one in pooled data (Hinkle et al., 2024) and with the suicidal behaviour in the COMP360 phase 2b trial. A claim that psychedelics cause psychosis in the general population goes beyond the Ontario cohorts, whose authors limit their conclusions to people who needed acute care. The absence of a reported harm also needs care, as the box below explains.
When nothing goes wrong
If a study of n people observes no cases of an event, the upper limit of the 95 percent confidence interval for the true risk is approximately 3 ÷ n for samples above about 30, the rule of three (Eypasch et al., 1995). A trial of 233 participants with no cases of an event is still compatible with a true risk of up to 3 ÷ 233, about 1.3 percent. Across the 3,504 participants pooled by Hinkle and colleagues (2024), the bound for HPPD would be about 0.09 percent, but only if every study had looked for it, and fewer than a quarter of recent studies assessed adverse events systematically.
A precise summary, as of October 2026, would say that serious psychiatric adverse events are uncommon in screened trial participants but occur in about 4 percent of patients in pooled data; that suicidal ideation and behaviour have occurred after psilocybin in depression trials, with an imbalance in one phase 2b trial that company-reported phase 3 data have not shown; that people with severe reactions outside clinics have higher later rates of psychotic and manic disorders; and that extended difficulties lasting a year or more occur at a frequency that surveys of self-selected samples cannot establish. Try it 6.2 asks you to apply this standard to a clinic's claim.
A hypothetical clinic's website states: "Psychedelic therapy has no serious psychiatric side effects. Trials have never recorded a case of psychosis, suicide or lasting harm." Write three sentences that correct the statement, each citing a source, and one sentence that states what remains unknown.
Suggested answer: In pooled data from 114 studies, about 4 percent of participants with neuropsychiatric conditions had a serious adverse event, including suicidal behaviour and psychosis (Hinkle et al., 2024). In the COMP360 phase 2b trial, three participants in the 25 mg group reported suicidal behaviour after week 3 (Goodwin et al., 2022). Prolonged adverse events have been described in trial participants (Wahba et al., 2024). The frequency of rare harms in people whom trials exclude, such as people with a family history of bipolar disorder, remains unknown.
6.1 Interpreting the Suicidality Signal
Several explanations remain open for the imbalance in suicidality adverse events in the COMP360 phase 2b trial. With fewer than 80 people per group, a difference of a few participants can arise by chance. The population had high baseline suicidality, and the timing, weeks after dosing among people who had not responded, is consistent with the course of severe depression after a treatment that did not help. All participants had stopped antidepressants, so discontinuation could have contributed to events in every group, although it cannot explain a difference between randomized groups. Equation 6.2 gives the measures for sizing such a difference.
Worked Example 6.2. The sponsor reported a suicidality adverse event in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg. The risks are 8.9 and 5.1 percent, the risk difference is 3.8 percentage points and the relative risk is 1.75. The number needed to harm is 1 ÷ 0.038 = 26.3, rounded up to 27. The 95 percent confidence interval for the risk difference (Newcombe's method) runs from −4.7 to 12.7 percentage points, and for the relative risk from 0.53 to 5.74, so the data are compatible with no difference, a small reduction or a substantial increase. Use Calculator 6.2 to repeat the calculation for serious events and for the Ontario cohort.
With fewer than 100 people per group, a trial cannot distinguish a moderate increase in risk from none, which is why full publication of the phase 3 data matters.
Psychiatric risks are real and uneven. The 2024 meta-analysis by Hinkle and colleagues (2024) found classic psychedelics generally well tolerated in research settings, although serious adverse events did occur, and the studies and reviews in this section point to risks concentrated in identifiable groups: people with a personal history of psychotic or bipolar I disorder, people with severe depression who do not respond, and people who use psychedelics in unsupported settings. Section 3 examines how screening decisions try to protect these groups and whom they may exclude unfairly.
Key Takeaways
- 5.1 Ontario cohorts found higher later rates of schizophrenia spectrum disorders (adjusted hazard ratio 3.53) and mania (weighted hazard ratio 5.97) after acute care involving hallucinogens, but they describe only people with severe reactions. Twin and survey studies point to genetic vulnerability, a personal history of psychotic or bipolar I disorder and use in illegal contexts as moderators, and trials exclude the people at highest risk, so each design shows only part of the picture.
- 5.2 In the COMP360 phase 2b trial, suicidal ideation, behaviour or self-injury occurred in all dose groups, and the three suicidal behaviours in the 25 mg group occurred at least a month after dosing in people who had not responded. Company-reported phase 3 statements describe no clinically meaningful imbalance, and pooled data from seven trials show large average decreases in suicidality, so the signal calls for clinical vigilance rather than a settled conclusion.
- 5.3 Hallucinogen persisting perception disorder is the distressing re-experiencing of perceptual distortions after use has stopped. It appears to be genuine but uncommon, has been reported most often after illicit LSD use and can persist for months or years, and its incidence has not been established; a 2024 meta-analysis found no cases reported in contemporary research settings.
- 5.4 Extended difficulties, such as anxiety, existential struggle, social disconnection, depersonalization and derealization, lasted more than a year for about one third of 608 people who reported them. Knowing the drug and dose, a less difficult acute experience and a guided setting were associated with milder courses, but self-selected surveys cannot give their frequency among everyone who uses psychedelics.
- 5.5 A precise statement of psychiatric risk separates what trials have observed from what they are too small or too selective to detect: serious psychiatric events occur in about 4 percent of patients in pooled data, and claims of no serious harm overstate the evidence. When a study of n people observes no cases, the rule of three still allows a true risk of up to about 3 ÷ n, and only if the study looked for the event.
- 6.1 The risk difference subtracts the proportion with an event in the comparison group from the proportion in the treated group, the relative risk divides the two, and the number needed to harm is the reciprocal of a positive risk difference. For suicidality adverse events in 7 of 79 and 4 of 79 participants, the risk difference is 3.8 percentage points and the number needed to harm 27, but the 95 percent confidence interval of −4.7 to 12.7 points includes zero, so the data are compatible with no difference, a small reduction or a substantial increase.
Reflection
You are drafting a paragraph for a patient information sheet for a hypothetical psilocybin trial in treatment-resistant depression. The facts available are these: in the COMP360 phase 2b trial, a suicidality adverse event occurred in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg (95 percent confidence interval for the difference, −4.7 to 12.7 percentage points); three participants in the 25 mg group reported suicidal behaviour after week 3, all at least a month after dosing and all among people who had not responded; and company-reported phase 3 statements found no clinically meaningful imbalance in suicidality between groups. Write the paragraph so that it neither overstates nor understates the risk, and state what follow-up the evidence implies.
Minimum 20 characters required.
Question 1: In the Ontario cohort of Myran et al. (2025a), the hazard ratio for a schizophrenia spectrum disorder after a hallucinogen emergency visit fell from 21.32 (age and sex adjusted) to 3.53 after further adjustment. What does this change most directly show?
Question 2: The sponsor of the COMP360 phase 2b trial reported a suicidality adverse event in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg. What are the risk difference and the number needed to harm?
Question 3: According to the sponsor's analysis of the COMP360 phase 2b trial, when did the suicidal behaviours occur?
Question 4: A hypothetical trial of 300 participants observes no cases of hallucinogen persisting perception disorder. By the rule of three, what is the approximate upper limit of the 95 percent confidence interval for the true risk?
Screening and Eligibility: Exclusion Criteria, Thresholds, Stabilization and Fair Access
Content note
This section discusses suicide risk assessment as part of screening. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).
Introduction
Sections 1 and 2 showed that the risks of psychedelics fall most heavily on identifiable groups: people with heart disease, people taking interacting medicines, people with a personal history of psychotic or bipolar disorders and people in acute crisis. Screening is the process of identifying those people before treatment, and it is the first safety step in every protocol. This section describes the criteria in current use, the thresholds behind them, the work of stabilization and medication review, and the people that screening may exclude unfairly.
Learning Objectives
- 7.1 Describe the psychiatric and medical exclusion criteria used in psychedelic trials and explain the rationale for each.
- 7.2 Interpret blood pressure and QTc thresholds for eligibility, and evaluate the evidence behind them.
- 7.3 Explain the purpose of stabilization before treatment and distinguish a deferral from an exclusion.
- 7.4 Describe how a medication review is carried out, and weigh the risks and benefits of tapering antidepressants before treatment.
- 7.5 Identify groups who may be excluded unfairly by current criteria, and apply screening criteria to hypothetical referrals.
Screening serves two purposes that do not always align. One is to protect the person, by keeping out anyone for whom the risk clearly outweighs the potential benefit. The other is to protect the validity of a trial, by enrolling a uniform group so that the effect of the treatment can be measured with less noise. A criterion that serves the second purpose may exclude people who could be treated safely. The distinction matters more as treatment moves from trials into practice, which Williams and colleagues (2026) describe as under way in Australia. In Canada, Alberta has required psychedelic drug treatment services to be licensed since 16 January 2023, a requirement its licensing page still described in October 2026 (Government of Alberta, 2022, 2025), and Lesson 11 describes both jurisdictions. Williams and colleagues (2026) reviewed the medical exclusion criteria registered for psychedelic trials, examined the rationale and medical basis of each, traced how they changed over 25 years and discussed which should apply in hospital practice. In Canada, Health Canada's expectations for clinical trials of psychedelic-assisted psychotherapy, published on 5 December 2022, state that a licensed physician should be involved in screening potential participants (Health Canada, 2022). Figure 6.5 shows the steps of a typical screening pathway.
The pathway has three outcomes, and the difference between the last two is important. An exclusion means that the person does not meet the criteria of a particular protocol. A deferral means that something can change, such as blood pressure, a crisis or a medication, and that the person will be reassessed. The rest of this section examines each step in turn, beginning with the psychiatric criteria.
7.1 Psychiatric and Medical Exclusion Criteria
7.1.1 Psychiatric Criteria
The psychiatric criteria follow directly from the evidence in Section 2. Johnson, Richards and Griffiths (2008) recommend excluding people with a current or past psychotic disorder, other than one induced by a substance or a medical condition, people with bipolar I or II disorder, and people with a first- or second-degree relative with these disorders. In studies of healthy volunteers they also exclude people with current or recent (within five years) alcohol or drug dependence, current major depression and several other current disorders. Recent trials in patient populations have adapted these rules to their own questions, and Table 6.5 lists the main criteria with the rationale for each.
Table 6.5. Common psychiatric exclusion criteria in psychedelic research, with the rationale for each and examples of sources that apply or question it.
| Criterion | Rationale | Examples |
|---|---|---|
| Current or past psychotic disorder | Risk of a persistent psychotic episode (Section 2) | Johnson et al. (2008); Knuijver et al. (2022) excluded any history of psychotic symptoms |
| Psychotic features in the current depressive episode | Overlap with psychosis risk | Goodwin et al. (2022) enrolled only major depression without psychotic features |
| Bipolar I or II disorder | Risk of mania | Johnson et al. (2008); Aaronson et al. (2024) deliberately tested bipolar II depression |
| A first- or second-degree relative with a psychotic or bipolar disorder | Inherited vulnerability | Johnson et al. (2008); Downey et al. (2024) propose stratified assessment |
| Clinically significant suicide risk | Safety during and after treatment | Goodwin et al. (2022); Knuijver et al. (2022) excluded suicidality and severe major depression |
| Current or recent substance dependence | Safety and interpretability in healthy-volunteer studies | Johnson et al. (2008); a 2021 MDMA phase 3 trial included people with a history of alcohol and substance use disorders (Mitchell et al., 2021) |
The table shows that criteria vary with the population and the question. A trial of MDMA-assisted therapy for severe post-traumatic stress disorder enrolled people with dissociation, depression, histories of alcohol and substance use disorders and childhood trauma, because these are common comorbidities of the disorder being treated (Mitchell et al., 2021). A study of ibogaine for opioid use disorder necessarily enrolled people who use opioids, and it excluded people with a history of psychotic symptoms, severe major depression or suicidality (Knuijver et al., 2022). The family-history criterion is contested (Downey et al., 2024), since it excludes many people who have never been ill, and Section 2 showed that the evidence on how much it adds to risk comes mainly from case studies, surveys and observational studies. Medical criteria are examined next.
7.1.2 Medical Criteria
Medical screening aims to find conditions that the drug's physical effects could worsen. Johnson, Richards and Griffiths (2008) recommend establishing good general health through a medical history, a physical examination, a 12-lead ECG, blood chemistry, hematology and urinalysis, and excluding people who are pregnant or not using effective contraception. Their blood pressure criterion excluded people whose resting blood pressure exceeded 140/90 mmHg, averaged across four assessments on at least two separate days. Drug-specific criteria follow from Section 1. The ibogaine study in Case 6.1 excluded people with a QTc above 450 ms (men) or 470 ms (women), abnormal potassium, severe liver or kidney disease and medicines that prolong the QT interval, with an exception for methadone, which participants were taking at screening and which was replaced with morphine for eight days before dosing (Knuijver et al., 2022).
7.2 Cardiovascular Thresholds and Where They Come From
Thresholds such as 140/90 mmHg are conventions chosen to be cautious, and they can be tested against data. The pooled analysis of 536 psilocybin sessions described in Section 1 argues that the 140/90 criterion was set conservatively without strong empirical support (Nayak et al., 2026). In those data, higher baseline blood pressure was associated with smaller increases after psilocybin, which the authors interpret as a ceiling effect, and they recommend broadening eligibility to blood pressure below 160/100 mmHg while continuing to exclude people with established cardiovascular disease. As of October 2026, the analysis was a preprint from a single research centre, so its recommendation awaits peer review and replication. Table 6.6 brings together the cardiovascular thresholds discussed in this lesson.
Table 6.6. Cardiovascular and ECG thresholds used for eligibility and during sessions, by source.
| Source | Measure | Threshold and its use |
|---|---|---|
| Johnson et al. (2008) | Resting blood pressure | Exclude above 140/90 mmHg, averaged across four readings on two days; antihypertensive medicine available during sessions |
| Nayak et al. (2026, preprint) | Resting blood pressure | Proposes eligibility below 160/100 mmHg for psilocybin, with established cardiovascular disease still excluded |
| Esketamine prescribing information (Janssen, 2026) | Blood pressure before and after each dose | Weigh the risk above about 140/90 mmHg; reassess at about 40 minutes; monitor for at least 2 hours |
| Knuijver et al. (2022) | QTc (correction not stated for the screening limits; Fridericia during monitoring) | Exclude above 450 ms (men) or 470 ms (women); give magnesium during monitoring above 500 ms |
| Drew et al. (2010) | QTc during drug treatment | Above 500 ms is highly abnormal; a value above 500 ms or an increase of 60 ms or more calls for prompt action |
The box below sets out how to read thresholds such as these.
Reading a threshold
A threshold divides a continuous measure into two groups, so people just above and just below it differ very little. A strict threshold reduces the chance of enrolling someone at risk and increases the number of people turned away who could have been treated safely; a permissive threshold does the reverse.
Judging a threshold involves three questions: what harm it is meant to prevent, what evidence links the measure to that harm in the population being treated, and what happens to the people it excludes. For blood pressure, Table 6.6 shows that the answers differ by drug, because esketamine, psilocybin and ibogaine affect the cardiovascular system in different ways and over different times.
Medical criteria, like psychiatric ones, separate people who are ready for treatment now from those who are not. Some conditions can change, and the next part of this section concerns the work of helping a person reach a state in which treatment is safe.
7.3 Stabilization and Suicide Risk Assessment
Stabilization is the process of treating or resolving an acute problem before psychedelic treatment begins. Typical reasons for deferral include a current crisis, uncontrolled blood pressure, and withdrawal from alcohol or benzodiazepines, which Alper, Stajić and Gill (2012) identified as a risk factor for seizures in deaths associated with ibogaine. Active suicidal intent or a recent suicide attempt is different: it makes the person ineligible at this time and calls for an immediate safety assessment and referral to crisis care. Trials have also selected people whose lives were stable enough to manage an intense experience and its aftermath: the ibogaine study in Case 6.1 enrolled people with a stable psychosocial situation, and its authors list this selection among the study's limitations (Knuijver et al., 2022).
Suicide risk assessment is a structured part of screening. Trials use the Columbia Suicide Severity Rating Scale, which asks about the presence, intensity and history of suicidal thoughts and behaviour, and the trial of psilocybin in bipolar II depression repeated it at every visit (Aaronson et al., 2024). The COMP360 phase 2b trial excluded people judged to be at clinically significant risk of suicide, so its results may not apply to people at high risk (Goodwin et al., 2022). This is the central tension of screening in depression: the people with the most severe illness may stand to gain, and they are also the people for whom an adverse turn after treatment would be most dangerous. Section 2 showed that suicidal behaviour in the phase 2b trial occurred weeks after dosing, which is why Health Canada (2022) expects check-in visits in the days and weeks after administration, and why Section 4 treats follow-up as part of safety.
When the concern is active suicidal intent or a recent attempt, the person is ineligible at this time and needs an immediate safety assessment and referral to crisis care, such as the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8); any later reassessment for psychedelic treatment would follow only after that care. Lesson 7 describes the safety plans that are built during preparation, and Section 4 of this lesson describes follow-up after dosing.
7.4 Medication Review and Tapering
A medication review records everything a person takes, including prescribed medicines, over-the-counter products, herbal preparations and non-prescribed substances, and checks each for interactions with the planned drug. Lesson 3 explains the pharmacology of these interactions, and the flip cards below summarize the categories a review must cover, drawing on the interactions listed by Johnson, Richards and Griffiths (2008) and the other sources cited.
Because serotonergic antidepressants may alter the psychedelic effect, a washout, in which the antidepressant is tapered and stopped before dosing, has been a common requirement for joining psilocybin trials (Goodwin et al., 2023), and a 2025 scoping review notes that protocols often require stopping antidepressants at least two weeks before dosing (Tap et al., 2025). In the COMP360 phase 2b trial, antidepressants were tapered and stopped at least two weeks before the baseline visit, and participants were asked to remain off them for the first three weeks after dosing (Goodwin et al., 2022); the trial in bipolar II depression stopped psychotropic medicines at least two weeks before dosing (Aaronson et al., 2024). Stopping an antidepressant carries its own risks. Horowitz and Taylor (2019) report that withdrawal syndromes occur often after stopping SSRIs, can be severe and can be mistaken for a return of depression. They note that guidelines recommend tapers of two to four weeks, while tapers over months to much lower doses have been more successful in reducing withdrawal symptoms.
The alternative is to give psilocybin alongside the antidepressant. In an open-label study, 19 participants with treatment-resistant depression received 25 mg of COMP360 while continuing an SSRI; 8 (42.1 percent) met criteria for response and remission at week 3, and there were no serious treatment-emergent adverse events (Goodwin et al., 2023). The study was small and uncontrolled, and its authors call for larger comparator-controlled trials. A 2025 scoping review of 18 studies found the combination of antidepressants and classic psychedelics generally safe and tolerable, with no increased risk of serotonin syndrome, particularly for psilocybin; its authors conclude that antidepressants can be maintained and call for randomized placebo-controlled trials (Tap et al., 2025). This evidence comes mainly from early studies, and research on it is evolving. In practice, any decision to taper belongs to the person and their prescriber, made with an honest account of what is known about both paths. Try it 6.3 applies these points to a hypothetical medication list.
A hypothetical person referred for psilocybin-assisted therapy reports taking sertraline (an SSRI) for depression, an antihistamine for allergies, St. John's wort bought at a health food store and occasional cannabis. Using the flip cards and the tapering evidence above, list the questions the screening team would raise about each item and say who should be involved in each decision.
Suggested answer: For sertraline, the team would ask whether the protocol requires a taper; if it does, the prescriber should plan the taper, allowing for withdrawal symptoms that can resemble relapse (Horowitz & Taylor, 2019), and if the protocol allows continuation, the team would note that SSRIs may reduce the response (Johnson et al., 2008; Goodwin et al., 2023). St. John's wort should be identified as a product to avoid (Johnson et al., 2008), and the person should know why. The antihistamine would be checked for interactions by the physician or pharmacist. Cannabis use would be recorded and discussed openly, without judgement, so that the person will disclose all substances; the protocol may specify a period without it. Each decision is shared between the person, the screening physician and, for prescribed medicines, the prescriber.
7.5 Who May Be Excluded Unfairly
Every exclusion criterion shifts risk from the person who is treated to the person who is turned away, who loses the potential benefit. Criteria that were set for trials may exclude people who could be treated safely in practice, and some exclusions fall more heavily on particular groups. This part of the section examines three sources of unfair exclusion.
The first is the narrowness of trial samples. Michaels and colleagues (2018) reviewed 18 psychedelic studies from 1993 to 2017 with 282 participants and found that 82.3 percent were non-Hispanic White, so reported outcomes may not generalize to all ethnic and cultural groups. A 2024 systematic review of 39 studies found that 85.0 percent of participants in pooled data were non-Hispanic White, with greater proportions of ethnic minoritized participants in studies published since 2018, particularly in the United States (Hughes & Garcia-Romeu, 2024); in one 2023 phase 3 trial of MDMA-assisted therapy, 26.9 percent of participants identified as Hispanic or Latino and 33.7 percent as other than White (Mitchell et al., 2023). Lesson 12 develops trial diversity, cost and public funding. The second source is criteria that are contested, such as the 140/90 mmHg blood pressure limit (Nayak et al., 2026) and the exclusion of everyone with a relative who has bipolar disorder (Downey et al., 2024), and the requirement to stop antidepressants that some people cannot stop safely (Goodwin et al., 2023; Tap et al., 2025). The third is practical. Protocols release people to the care of a friend or family member (Johnson et al., 2008) and require several preparation and integration visits and a full day for dosing, which disadvantages people who live alone, cannot take time off work or live far from a treatment site. The accordion below separates these kinds of exclusion.
Criteria such as a current psychotic disorder, a QTc above 500 ms, or active suicidal intent exclude people for whom the risk is high and the evidence is reasonably clear. They are the criteria least likely to be relaxed in practice, although the person still needs another form of care.
Criteria that make a sample uniform, such as excluding common comorbid conditions, make an effect easier to detect. When treatment moves into practice, these criteria may no longer be needed, and Williams and colleagues (2026) examine which medical criteria should carry over into hospital psychiatry.
The lack of a companion, distance or the cost of time off are barriers that a service can often remove. Johnson et al. (2008) describe the option of an overnight stay at the research site, and Health Canada (2022) states that lodging should be available on the day of administration. Treating a logistical barrier as an exclusion would disadvantage the people who face it.
Interactive 6.1 asks you to apply the criteria in this section to seven hypothetical referrals. For each one, choose the decision that the stated criteria support, then check your choices and read the feedback, which notes where the criteria themselves are contested.
All referrals are hypothetical. For each, choose the decision that the criteria described in this section support.
Screening reduces risk, and the exercise shows that it also involves judgement about evidence, timing and fairness. However careful it is, screening cannot remove every risk: Sections 1 and 2 showed that screened participants still have difficult experiences, blood pressure excursions and, occasionally, serious adverse events. Section 4 turns to how teams manage these events when they occur, and how support is offered to people who use psychedelics outside clinics.
Key Takeaways
- 7.1 Psychiatric criteria commonly exclude people with a current or past psychotic disorder, bipolar I or II disorder, a first- or second-degree relative with these disorders or clinically significant suicide risk, and healthy-volunteer studies also exclude recent substance dependence; trials adapt these rules to their population and question. Medical screening uses a history, examination, 12-lead ECG and blood tests to find conditions the drug could worsen, with drug-specific criteria such as QTc limits, potassium and QT-prolonging medicines for ibogaine.
- 7.2 Thresholds such as 140/90 mmHg for resting blood pressure and 450 ms (men) or 470 ms (women) for QTc are cautious conventions that divide a continuous measure, and a 2026 preprint proposes a limit below 160/100 mmHg for psilocybin. Judging a threshold means asking what harm it prevents, what evidence links the measure to that harm in the population treated and what happens to the people it excludes, and the answers differ by drug.
- 7.3 Stabilization treats or resolves an acute problem, such as a crisis, uncontrolled blood pressure or withdrawal from alcohol or benzodiazepines, before treatment; a deferral means the person will be reassessed, while an exclusion means the protocol's criteria are not met. Active suicidal intent or a recent attempt makes a person ineligible at this time and calls for an immediate safety assessment and crisis care, and structured suicide risk assessment with the C-SSRS is part of screening.
- 7.4 A medication review records prescribed, over-the-counter, herbal and non-prescribed substances and checks each for interactions, including serotonergic antidepressants, lithium, monoamine oxidase inhibitors, St. John's wort and drugs that prolong the QT interval. Antidepressant washouts have been common in trials, but withdrawal is frequent, can be severe and can mimic relapse, and one small open-label study gave psilocybin alongside an SSRI, so any taper is a decision for the person and their prescriber.
- 7.5 Narrow trial samples, contested criteria, such as the 140/90 mmHg limit, blanket family-history exclusion and required washouts, and practical demands such as a companion at discharge can exclude people unfairly. Separating exclusions that protect the person from those that protect the trial and from logistical barriers that a service can remove shows which criteria should carry into practice, as the screening decisions in Interactive 6.1 illustrate.
Reflection
A hypothetical 58-year-old with treatment-resistant depression is referred to a psilocybin study whose protocol follows Johnson, Richards and Griffiths (2008) and the COMP360 phase 2b trial. Four features stand out: resting blood pressure averages 148/92 mmHg across four readings on two days; their father was diagnosed with bipolar I disorder at age 45; they take venlafaxine, a serotonergic antidepressant, and the protocol requires stopping it at least two weeks before baseline; and they live alone with no one to accompany them home. For each feature, state whether it leads to deferral, exclusion or a solvable barrier under these criteria, and argue whether any of the criteria should be revisited, citing evidence from this lesson.
Minimum 20 characters required.
Question 1: Which blood pressure criterion did Johnson, Richards and Griffiths (2008) describe for excluding volunteers?
Question 2: A hypothetical person with depression made a suicide attempt three weeks ago and reports current suicidal intent. Which screening decision do the criteria in this lesson support?
Question 3: What concern about antidepressant tapering do Horowitz and Taylor (2019) raise that bears on trial washout periods?
Question 4: A hypothetical person meets every criterion but lives alone and has no one to accompany them home after dosing. How does this lesson classify that issue?
Managing Difficult Experiences and Medical Events: Response, Aftercare and Support Outside Clinics
Content note
This section discusses medical emergencies and follow-up for suicidal thoughts and behaviour after treatment. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).
Introduction
Screening lowers risk without removing it. Section 1 showed that blood pressure rises during psilocybin sessions, with systolic pressure crossing 170 mmHg in about 6 percent of the sessions pooled in one research centre's 2026 preprint, and Section 2 showed that serious psychiatric events occur in a small proportion of patients even in trials. In research settings, difficult moments during a session have mostly been psychological and have passed with support (Johnson et al., 2008), and adverse events needing medical intervention have been rare (Hinkle et al., 2024); medical events still need a response that has been planned before the session starts. Health Canada's expectations for clinical trials state that contingency plans should be established for potential serious adverse events (Health Canada, 2022). This section follows the response from the least to the most intensive step, then turns to discharge, aftercare and the support available to people who use psychedelics outside clinics. Figure 6.6 shows the steps.
Learning Objectives
- 8.1 Describe the stepwise approach to supporting a person through a difficult experience during a session, and explain why reassurance comes first.
- 8.2 Explain when rescue medication is used, which medicines published guidelines recommend, and how rarely they have been needed.
- 8.3 Describe the elements of an emergency protocol for medical events, and evaluate a session record against a safety checklist.
- 8.4 State discharge criteria and the components of aftercare, including follow-up for suicidality and extended difficulties.
- 9.1 Describe peer support lines and festival sanctuary services in Canada and the United States, and explain what each can and cannot do.
- 9.2 State the protection that the Good Samaritan Drug Overdose Act provides and the legal limits that apply to regulated practitioners in Canada.
8.1 Supporting a Person Through a Difficult Experience
Difficult experiences during a session include fear, panic, confusion, grief and painful memories. Lesson 5 described how often they occur, and Lesson 7 describes the therapist's role in the session; this part concerns the first two steps in Figure 6.6.
Johnson, Richards and Griffiths (2008) state that the appropriate first response to acute distress is strong personal support and reassurance. They warn that attempts to "talk down" a person may be counterproductive and aggravate a difficult reaction, and they describe holding the person's hand as a powerful form of reassurance. They encourage participants to let the experience unfold and to move toward difficult material when it arises, and they recommend at least two monitors so that the participant is never alone when one of them steps out. In their own studies, reassurance had been sufficient to handle every case of acute psychological distress among 54 volunteers who received high doses of psilocybin. This guidance rests mainly on experience in research settings. The flip cards below summarize the principles that recur in published guidance.
The second step adjusts the setting, which can include reducing light and noise, changing or pausing music, helping the person change position, offering water or a blanket, and grounding attention in breathing or in the room. Lesson 5 reviewed the evidence on music and environment. When these steps are not enough, or when measurements suggest a medical problem, the response moves to a physician's assessment and, rarely, to medication.
8.2 Rescue Medication
A rescue medication is a drug given to relieve severe distress or a dangerous physical effect during a session. Johnson, Richards and Griffiths (2008) describe pharmacological intervention as a last resort that should rarely, if ever, be needed. For severe anxiety, they recommend an oral benzodiazepine, such as diazepam, as the intervention of choice. They state that antipsychotic medicines such as risperidone or olanzapine should be available, while noting that their effects may be abrupt, unpleasant and intense, that haloperidol should not be used as a rescue medication, and that ketanserin, a 5-HT2A antagonist, might serve as one, although it is not approved in the United States. Antihypertensive medicine should be immediately available in case blood pressure exceeds the protocol's limits.
Frequency data support this description. In one research centre's pooled data, reported in a 2026 preprint, antihypertensive medicine was given in one of 536 psilocybin sessions (Nayak et al., 2026). In the meta-analysis by Hinkle and colleagues (2024), non-serious adverse events that required medical intervention, such as paranoia or headache, were similarly rare to serious events. The box below explains why teams still prepare for them.
Why prepare for events that rarely happen
A sedating medicine relieves severe anxiety, and it may also alter the experience on which the treatment depends, so the decision balances the person's immediate safety against the therapeutic aim. The consent process tells the person in advance when such medicines might be offered (Lesson 7).
Preparing for rare events is a matter of probability over many sessions. At a hypothetical service that runs ten sessions a week, or about 520 a year, an event that occurs once in 500 sessions has about a 65 percent chance of occurring at least once in a year, so the medicine, the dose, the person authorized to give it and the record that documents it must be settled in the protocol before the first session.
8.3 Emergency Protocols for Medical Events
An emergency protocol states, before any session, who is responsible, what is measured and when, what each threshold triggers and how a person is transferred to hospital. Health Canada (2022) expects a licensed physician to be readily available on site for the duration of the drug's effects in trials of psychedelic-assisted psychotherapy, contingency plans for serious adverse events, and the reporting of serious unexpected adverse drug reactions to Health Canada. In Alberta, licensed psychedelic drug treatment services must report on complaints and must report critical incidents, defined as incidents that cause or threaten to cause serious injury or death (Government of Alberta, 2022, 2025). Table 6.7 sets out the medical events discussed in this lesson with the prepared responses described in the sources.
Table 6.7. Medical events discussed in this lesson, with the prepared response described in each source.
| Event | How it is detected | Prepared response in the sources |
|---|---|---|
| Blood pressure excursion during psilocybin or MDMA | Measurements timed to the peak (about 90 minutes for psilocybin) | Recheck; antihypertensive medicine available (Johnson et al., 2008); most excursions are brief (Nayak et al., 2026, preprint) |
| Blood pressure rise after esketamine | Measurement before the dose and at about 40 minutes | Monitoring for at least two hours after each dose (Janssen, 2026) |
| QTc prolongation after ibogaine | Repeated 12-lead ECGs for at least 24 hours, continued if a cardiologist judges it necessary | Magnesium infusion above 500 ms and transfer to a coronary care unit for continuous monitoring if needed (Knuijver et al., 2022) |
| Rising body temperature with MDMA | Temperature measurement during the session (Vizeli & Liechti, 2017) | Medical assessment; hyperpyrexia and hyponatremia need hospital care (Hall & Henry, 2006; Campbell & Rosner, 2008) |
| Seizure | Observation; risk factors identified at screening | Screening for lithium and for alcohol or benzodiazepine withdrawal (Nayak et al., 2021; Alper et al., 2012); emergency transfer |
A checklist turns a protocol into steps that a team can verify. Interactive 6.2 presents the record of a hypothetical psilocybin session in an authorized Canadian trial. Read the record, decide whether each item on the checklist was met, and then check your answers; the feedback sorts any gaps by when they would have to be fixed.
A session can meet most requirements and still leave gaps that matter, such as a physician who cannot reach the room quickly, measurements that miss the peak and a discharge without support. Closing the last of these gaps depends on what happens after the person leaves the clinic.
8.4 Discharge and Aftercare
Safety continues after the acute effects end. Discharge criteria decide when a person may leave, and aftercare covers the months that follow.
8.4.1 Discharge
Johnson, Richards and Griffiths (2008) describe releasing participants only after the effects of the drug have resolved, into the care of a friend or family member whom staff have oriented to provide emotional support, or keeping them overnight at the research site. Participants are told not to drive or engage in other potentially dangerous activities for the rest of the day, and they receive a number to call. Health Canada (2022) states that lodging should be available on the day the drug is given. For esketamine, the prescribing information requires monitoring for at least two hours and advises against driving until the next day after a restful sleep (Janssen, 2026).
8.4.2 Aftercare and Follow-Up
Johnson, Richards and Griffiths (2008) recommend one or more meetings after each session, typically the next day, and they advise asking about perceptual disturbances at follow-up (Section 2). Health Canada (2022) expects check-in visits in the days and weeks after administration because mental health may worsen after treatment sessions. The timing of the events in Section 2 shows why follow-up must extend beyond the first few days: in the COMP360 phase 2b trial, most serious suicidality events occurred at least a week after the session, and all suicidal behaviours occurred at least a month after it, in people who had not responded (Compass Pathways, 2021). Follow-up therefore tracks response as well as safety, and a person who has not improved needs a plan for further care (Figure 6.7).
Two further elements complete aftercare. The first is a safety plan, a written list of warning signs, coping strategies, people to contact and services to use if suicidal thoughts arise. In Veterans Health Administration emergency departments in the United States, the Safety Planning Intervention with at least two follow-up calls was associated with suicidal behaviour in 3.03 percent of patients over six months, against 5.29 percent with usual care (odds ratio 0.56) (Stanley et al., 2018). That evidence comes from another setting, but it supports building a plan during preparation (Lesson 7) and reviewing it at follow-up. The second element is a referral pathway for extended difficulties, which can last for months (Section 2; Lesson 7).
9.1 Support Outside Clinical Settings
Lesson 1 showed that most psychedelic use happens outside clinics, without screening, monitoring or aftercare. Harm reduction is the public health approach that aims to reduce the harms of drug use without requiring that people stop using, and HSCI 402 develops harm reduction services, including drug checking. This part of the section describes the services that support people outside clinics and the legal position of practitioners in Canada; it describes services and principles and gives no advice on using any drug.
9.1.1 Peer Support Lines
Fireside Project, a non-profit organization in the United States, launched its Psychedelic Support Line in 2021. As of October 2026, it offers free, confidential peer support by call or text at 62-FIRESIDE (623-473-7433) from 11 a.m. to 11 p.m. Pacific time every day, staffed by trained volunteers, and it serves callers in the United States only, with a stated aim of expanding to Canada. It states that it does not provide mental health, clinical or medical services, that it is not a suicide hotline, and that people in an emergency should call emergency services (Fireside Project, 2026); in Canada, these are 9-1-1 and the 9-8-8 Suicide Crisis Helpline. Pleet and colleagues (2023) analyzed data from 884 callers to the line: 65.9 percent said the call had de-escalated them from psychological distress, 29.3 percent said that without it they might have been harmed, and 10.8 percent said they might have gone to an emergency room. These are callers' own judgements without a comparison group, so they suggest benefit without measuring it.
9.1.2 Festival Sanctuary Services
Sanctuary services are quiet spaces at events where trained staff or volunteers support people through difficult experiences. At the Shambhala Music Festival in rural British Columbia, ANKORS, a harm reduction organization based in Nelson, has provided harm reduction services since 2003, including drug checking (Mema et al., 2018). In October 2026, the festival's website described a Sanctuary next to its medical services, open 24 hours a day and staffed by experienced professionals, for anyone feeling stressed, overwhelmed or isolated or experiencing anxiety, panic, hallucinations, delusions or dissociation (Shambhala Music Festival, 2026). In Toronto, TRIP!, a peer harm reduction project, has offered peer harm reduction at events and drop-in sessions for about 30 years, as it described its work in 2025 (TRIP!, 2026). In the United States, the Zendo Project has run a support space at the Burning Man event since 2012, as its website described in 2026, and trains volunteers to support people at events without trying to fix or guide their experience (Zendo Project, 2026).
9.1.3 User-Facing Resources
Online resources reach people before and during use. TripSit offers a live chat with volunteers, who state that they hold no professional certification, along with drug factsheets and a chart of drug combinations (TripSit, 2026). PsychonautWiki describes itself as a community-driven online encyclopedia of psychonautics (PsychonautWiki, 2026), and Lesson 1 discussed its Subjective Effect Index. MAPS Canada, a volunteer-run organization, offers public education and psychedelic safety resources (MAPS Canada, 2026). These resources record what people who use psychedelics report and publish harm reduction information; they cannot establish the efficacy or safety of any drug. Table 6.8 compares the services described here.
Table 6.8. Support services for people who use psychedelics outside clinics, with what each offers and what it cannot do, as described by each organization in 2026.
| Service | What it offers | What it cannot do |
|---|---|---|
| Fireside Project support line | Peer support by phone or text, daily 11 a.m. to 11 p.m. Pacific | Clinical, medical or crisis care, or service to callers in Canada (as of October 2026) |
| Festival sanctuary spaces (Shambhala; Zendo Project) | A calm space and in-person support at an event | Follow-up after the event |
| Peer event programs (TRIP!) | Peer harm reduction education and supplies at events and drop-ins | Medical assessment or treatment |
| Online resources (TripSit, PsychonautWiki) | Volunteer chat and user-reported information | Establish safety or efficacy, or replace medical care |
| Emergency services (9-1-1) | Medical assessment, treatment and transport | Peer support |
9.2 Legal Protections and Limits in Canada
Fear of police can delay a call for help. Canada's Good Samaritan Drug Overdose Act, in force since 4 May 2017, protects people who seek emergency help during an overdose, including the person who has overdosed and others at the scene, from charges for simple possession of a controlled substance; it does not protect against charges for trafficking or production or against outstanding warrants (Health Canada, 2026). The box below explains a different legal limit, which applies to regulated practitioners.
The legal limits on practitioners in Canada
This box gives legal information, not legal advice. Under subsection 4(1) of the Controlled Drugs and Substances Act, "Except as authorized under the regulations, no person shall possess a substance included in Schedule I, II or III." As of October 2026, psilocybin, psilocin, LSD, DMT and mescaline are listed in Schedule III, and MDMA and ketamine in Schedule I. Under section 21 of the Criminal Code, everyone is a party to an offence who actually commits it, does or omits to do anything for the purpose of aiding any person to commit it, or abets any person in committing it.
Taken together, these provisions mean that a regulated professional who provides preparation or integration support for the unauthorized use of a scheduled psychedelic may be at legal risk of being a party to the offence of possession, in addition to the professional consequences that a regulatory college may impose. Section 56 of the Act allows the Minister of Health to grant exemptions. Exemptions, clinical trials and the Special Access Program are the authorized routes that Lesson 11 describes; since the federal Controlled Substances Regulations (SOR/2025-242) came into force on 1 October 2026, the Special Access Program for restricted drugs such as psilocybin and MDMA has operated under those regulations, which absorbed the earlier section 56 class exemption for that program.
Ibogaine is not listed in the Act and is on Health Canada's Prescription Drug List (Section 1). Lesson 7 explains how the law shapes preparation and integration practice.
Since 16 January 2023, Alberta has required providers of psychedelic drug treatment for psychiatric disorders to hold a licence, to appoint a psychiatrist as medical director, to have the drug prescribed only by a psychiatrist or a physician consulting a psychiatrist, to have psychotherapy delivered by qualified regulated professionals such as psychiatrists and clinical psychologists, to have authorized professionals monitor and care for patients while they are in an altered state of consciousness, and to report on complaints and critical incidents (Government of Alberta, 2022); its licensing page still described the licensing requirement and psychiatrist oversight in October 2026 (Government of Alberta, 2025). Using this lesson, (1) name two safety elements that these requirements address directly, (2) name three elements they do not specify, which a provider's protocol would need to set out, and (3) write the rule you would include for one of them, with its source.
Suggested answer: (1) Monitoring during altered states addresses the session safety of Sections 1 and 4, and critical incident reporting supports the adverse event surveillance that Hinkle et al. (2024) found weak in research. (2) The summary does not specify screening criteria (Section 3), the timing of blood pressure measurements and the thresholds that trigger action (Sections 1 and 4), or discharge and follow-up rules, including follow-up for suicidality (Sections 2 and 4). (3) A follow-up rule could read: "Every patient has a follow-up meeting the day after each session and check-ins over the following weeks, with an assessment of response and of suicidal thoughts at each contact," based on Johnson et al. (2008), Health Canada (2022) and the timing reported by Compass Pathways (2021).
This section has followed the response to difficulty from a hand held in reassurance to an emergency transfer, and from discharge to follow-up over months. Together with the physical risks of Section 1, the psychiatric risks of Section 2 and the screening of Section 3, it describes how psychedelic-assisted therapy manages risk: by knowing the drug, selecting and preparing the person, controlling the setting, planning for rare events and continuing care after the session. The reflection and the final assessment below ask you to bring these parts together.
Key Takeaways
- 8.1 The first response to acute distress is strong personal support and reassurance, with at least two monitors so that the person is never alone, touch only as agreed, and no attempt to talk the person down. The second step adjusts the setting and grounds the person's attention, and measurements continue because distress can mask a medical problem.
- 8.2 Rescue medication is a last resort: an oral benzodiazepine such as diazepam for severe anxiety, antipsychotics available although their effects can be abrupt, no haloperidol, and antihypertensive medicine on hand. It has rarely been needed, with antihypertensive medicine given in one of 536 pooled psilocybin sessions reported in a 2026 preprint, but over hundreds of sessions a year a rare event becomes likely, so the medicine, dose and authority to give it are settled before the first session.
- 8.3 An emergency protocol states who is responsible, what is measured and when, what each threshold triggers and how a person is transferred to hospital, and Health Canada expects a physician readily available on site for the duration of the effects and contingency plans in trials. Checking a session record against a safety checklist shows that a session can meet most requirements and still leave gaps, such as an off-site physician or measurements that miss the peak.
- 8.4 Discharge follows the resolution of the drug's effects, into the care of an oriented companion or overnight lodging, with no driving that day and a number to call. Aftercare includes a next-day meeting, check-ins over the following weeks, a written safety plan and a referral pathway for extended difficulties, and follow-up must extend for months because suicidal behaviour in the phase 2b trial occurred at least a month after dosing in people who had not responded.
- 9.1 Peer support lines such as Fireside Project, festival sanctuary spaces such as Shambhala's, peer programs such as TRIP! and online resources such as TripSit support people who use psychedelics outside clinics. Each works within clear limits: none provides clinical or crisis care, sanctuary spaces offer no follow-up, and online resources cannot establish safety, so medical emergencies in Canada go to 9-1-1 and suicidal crises to 9-8-8.
- 9.2 Canada's Good Samaritan Drug Overdose Act protects people who seek emergency help during an overdose from charges for simple possession, but not from trafficking or production charges or outstanding warrants. A regulated professional who supports the unauthorized use of a scheduled psychedelic may be at legal risk as a party to possession under subsection 4(1) of the Controlled Drugs and Substances Act and section 21 of the Criminal Code, and exemptions, clinical trials and the Special Access Program are the authorized routes.
Reflection
A hypothetical friend tells you they intend to take psilocybin mushrooms at a music festival in British Columbia and asks what support exists if something goes wrong. You are a health sciences student, not a clinician, and you will not give advice on using the drug. Using only the services and principles described in Section 4 (a festival sanctuary space next to medical services, such as the one Shambhala describes; Fireside Project's peer support line, which served callers in the United States only in October 2026; 9-1-1 and the Good Samaritan Drug Overdose Act; and user-facing resources such as TripSit), describe what you would tell your friend about the support available and what each source can and cannot do.
Minimum 20 characters required.
Question 1: According to Johnson, Richards and Griffiths (2008), what is the appropriate first response when a participant becomes acutely distressed during a session?
Question 2: What did Health Canada's December 2022 expectations for clinical trials of psychedelic-assisted psychotherapy say about physicians?
Question 3: Which statement about the Fireside Project's support line is accurate as of October 2026?
Question 4: What protection does Canada's Good Samaritan Drug Overdose Act (in force since 4 May 2017) provide?
Final Assessment
Bringing It All Together
This lesson has examined the risks of psychedelics and how psychedelic-assisted therapy manages them. Section 1 showed that physical risks follow from pharmacology and setting: transient rises in blood pressure that protocols monitor at the right times, MDMA hyperthermia and hyponatremia that concentrate in hot and crowded events, the QT prolongation behind deaths associated with ibogaine, the unresolved 5-HT2B question for repeated dosing and ketamine cystitis with frequent use. Section 2 showed that psychiatric risks are real and uneven, from psychosis and mania in vulnerable people to suicidality in depression trials and extended difficulties that can last for years, and that each type of study sees only part of the picture.
Sections 3 and 4 turned to the response. Screening uses psychiatric and medical criteria, thresholds and medication review to identify people at high risk, and it involves judgement about evidence, timing and fairness. Management during and after a session moves from reassurance to emergency transfer, and aftercare continues for months because some serious events occur weeks after dosing. Outside clinics, peer support lines and sanctuary services offer support within clear limits, and the law sets limits on what regulated practitioners may do.
Key Takeaways from this lesson
- Psilocybin raised systolic blood pressure by about 19 mmHg on average in supervised studies, with the largest changes 60 to 90 minutes after dosing (a 2026 review), and esketamine's rise peaks at about 40 minutes, so monitoring must be timed to the drug.
- MDMA can cause hyperthermia and hyponatremia, and heat, crowding, exertion, heavy fluid intake and unknown doses explain why these harms concentrate outside clinics.
- Ibogaine and noribogaine lengthen the QT interval through hERG channel inhibition seen in cell studies, and a QTc corrected by Bazett's or Fridericia's formula can fall on either side of a threshold; most deaths in a 2012 review involved pre-existing heart disease or other drugs, and a 2026 review notes arrhythmias in people without known heart disease.
- The link between 5-HT2B receptors and valvular heart disease is supported by cell evidence and one small human study for MDMA, and a 2023 review found no study designed to test it for repeated classic psychedelic dosing, so for these drugs the risk remains largely speculative; ketamine-associated cystitis rises with dose and frequency of use.
- Psychosis appears uncommon in trials, on mostly low-quality evidence (a 2025 meta-analysis), while population studies link severe reactions to hallucinogens with later psychotic and manic disorders. Suicidal ideation, suicidal behaviour or self-injury occurred in all dose groups of the 2022 COMP360 phase 2b trial, and extended difficulties can last for more than a year in some people who report them. Trials exclude the people at highest risk and are too small to detect rare harms.
- Risk differences, relative risks and numbers needed to harm size an imbalance in adverse events, and their wide confidence intervals in small trials, like the rule of three when no events occur, show how much remains compatible with the data.
- Screening distinguishes exclusion from deferral, and some criteria, such as the 140/90 mmHg limit, family history and antidepressant washouts, rest on limited evidence and may exclude people unfairly.
- Reassurance is the first response to distress, medication is a last resort, and emergency protocols, discharge to a companion or lodging, and follow-up over months complete the safety plan.
- Peer support lines, festival sanctuary services and user-facing resources help people outside clinics within clear limits, the Good Samaritan Drug Overdose Act protects people who call for help during an overdose from simple possession charges, and Canadian law can expose regulated practitioners who support unauthorized use to legal risk.
Core Concepts Reviewed
Section 1: blood pressure excursions and their timing, hyperthermia, hyponatremia and vasopressin, the QT interval and its correction, hERG inhibition and torsades de pointes, 5-HT2B receptors and valvular heart disease, and ketamine-associated cystitis.
Section 2: psychosis and mania with personal and family history, suicidality signals in trials, risk differences and numbers needed to harm, hallucinogen persisting perception disorder, extended difficulties and the rule of three.
Section 3: psychiatric and medical exclusion criteria, blood pressure and QTc thresholds, stabilization and deferral, suicide risk assessment, medication review and antidepressant tapering, and unfair exclusion.
Section 4: de-escalation and reassurance, rescue medication, emergency protocols, discharge criteria, aftercare and safety plans, peer support lines, sanctuary services, the Good Samaritan Drug Overdose Act and the legal limits on practitioners.
The final reflection asks you to bring the four sections together in the safety section of a treatment protocol.
Reflection
Design the safety section of a protocol for a hypothetical psilocybin-assisted therapy program for treatment-resistant depression in British Columbia, operating through an authorized route. Address four parts: (1) screening, including at least two psychiatric and two medical criteria; (2) the dosing session, including staffing, measurements and their timing, and rescue medication; (3) discharge; and (4) follow-up over the months after dosing. Cite at least five sources from this lesson, and identify one criterion you would relax and one you would keep, with reasons.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: A hypothetical service plans to give esketamine and psilocybin in different programs. Which monitoring plan matches the evidence in Section 1?
Question 2: How do the MDMA harms in Section 1 and the extended difficulties in Section 2 point to the same lesson about setting?
Question 3: A hypothetical 47-year-old man who takes methadone for opioid use disorder asks to join an ibogaine study that uses the criteria of Knuijver et al. (2022). His screening QTc is 462 ms. Which decision and reason fit the evidence?
Question 4: Hinkle et al. (2024) found serious adverse events in about 4 percent of trial participants with neuropsychiatric conditions and systematic adverse event assessment in only 23.5 percent of recent studies. What follows for consent and public claims?
Question 5: A hypothetical screening team considers excluding a person whose aunt has bipolar I disorder. Which statement best reflects this lesson?
Question 6: How should a team treat the recommendation of Nayak et al. (2026) to broaden blood pressure eligibility for psilocybin to below 160/100 mmHg?
Question 7: Which follow-up schedule best fits both Health Canada's 2022 expectations and the timing of suicidality events in the COMP360 phase 2b trial?
Question 8: Which statement about rescue medication matches the safety guidelines of Johnson, Richards and Griffiths (2008)?
Question 9: A hypothetical trial of 150 participants reports no cases of a serious adverse event. What is the approximate upper limit of the 95 percent confidence interval for its true risk, and what caution applies?
Question 10: A hypothetical client cites PsychonautWiki and TripSit as proof that combining two drugs is safe. How should a practitioner describe these sources?
Question 11: A hypothetical registered counsellor in British Columbia offers preparation sessions for clients planning to use psilocybin obtained without authorization. What legal position does this lesson describe?
Question 12: What does the evidence in Section 1 suggest about the bladder risks of ketamine?
Question 13: Why do the authors of the Ontario study of mania after hallucinogen acute care (Myran et al., 2025b) limit the generalizability of their findings?
Question 14: In a hypothetical trial session, the study physician works at a hospital across town and can be reached by phone. When must this gap be closed, according to Health Canada's 2022 expectations?
Question 15: A hypothetical person referred for psilocybin takes lithium prescribed by a psychiatrist. Which response integrates Sections 3 and 4 with Lesson 3?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Terms, tools and people from this lesson on the safety of psychedelics, screening and the management of risk.